Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP, Research & CSO | August 09, 2022 | August 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vir Biotechnology, Inc.
Report date August 09, 2022 · Filed August 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,500 |
Ending reported balance
After 2022-08-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-08-09 · Exercise / conversion · Acquired 70,177 · Balance 254,584 Row 2 · 2022-08-09 · Exercise / conversion · Acquired 7,916 · Balance 262,500 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2028-01-26 | Direct | 140,328 |
Reported balance
After 2022-08-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-09 · Exercise / conversion · Disposed 70,177 · Balance 140,328 F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2029-07-12 | Direct | 125,416 |
Reported balance
After 2022-08-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-09 · Exercise / conversion · Disposed 7,916 · Balance 125,416 F2: 1/4 of the shares subject to the stock option vested and become exercisable on July 12, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested and exercisable.
F2: 1/4 of the shares subject to the stock option vested and become exercisable on July 12, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 09, 2022 Filed Aug 10, 2022 20:50 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,916 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001209191-22-045230 · doc4.xml · derivative · entry 4 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,416 Underlying: Common Stock · 7,916 shares Expires 2029-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and become exercisable on July 12, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:50 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 70,177 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-22-045230 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,328 Underlying: Common Stock · 70,177 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:50 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 7,916 | $10.40 | $82,286.82 |
DisclosureSEC source: 0001209191-22-045230 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:50 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 70,177 | $1.53 | $107,370.81 |
DisclosureSEC source: 0001209191-22-045230 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-22-018153 · doc4.xml · derivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,505 Underlying: Common Stock · 9,000 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 9,000 | $1.53 | $13,770.00 |
DisclosureSEC source: 0001209191-22-018153 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $29.48 | $0.00 |
DisclosureSEC source: 0001209191-22-012952 · doc4.xml · derivative · entry 5 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-02-21 F4 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-22-012952 · doc4.xml · derivative · entry 4 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,505 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $30.00 | $41,250.00 |
DisclosureSEC source: 0001209191-22-012952 · doc4.xml · nonDerivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,407 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-22-012952 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:30 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-012952 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,407 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:02 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,293 | $31.93 | $73,217.55 |
DisclosureSEC source: 0001209191-22-011755 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,407 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 08, 2022 Filed Feb 9, 2022 23:58 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-22-008208 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,880 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 08, 2022 Filed Feb 9, 2022 23:58 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $33.94 | $46,667.50 |
DisclosureSEC source: 0001209191-22-008208 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| February 08, 2022 Filed Feb 9, 2022 23:58 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-22-008208 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 00:35 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-22-005117 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,255 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 00:35 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $32.46 | $44,632.50 |
DisclosureSEC source: 0001209191-22-005117 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 00:35 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-22-005117 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:09 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-22-003175 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,630 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:09 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $35.10 | $48,262.50 |
DisclosureSEC source: 0001209191-22-003175 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:09 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-22-003175 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-071611 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,005 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $39.95 | $54,931.25 |
DisclosureSEC source: 0001209191-21-071611 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-071611 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,750 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-069994 · doc4.xml · derivative · entry 6 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,380 Underlying: Common Stock · 2,750 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,750 | $50.00 | $137,500.00 |
DisclosureSEC source: 0001209191-21-069994 · doc4.xml · nonDerivative · entry 4 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| December 15, 2021 Filed Dec 16, 2021 22:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 2,750 | $1.53 | $4,207.50 |
DisclosureSEC source: 0001209191-21-069994 · doc4.xml · nonDerivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-069994 · doc4.xml · derivative · entry 5 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,130 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $45.88 | $63,085.00 |
DisclosureSEC source: 0001209191-21-069994 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:04 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-069994 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,125 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-067659 · doc4.xml · derivative · entry 4 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,505 Underlying: Common Stock · 15,125 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 13,750 | $50.00 | $687,500.00 |
DisclosureSEC source: 0001209191-21-067659 · doc4.xml · nonDerivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $45.60 | $62,700.00 |
DisclosureSEC source: 0001209191-21-067659 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,450 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:12 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 15,125 | $1.53 | $23,141.25 |
DisclosureSEC source: 0001209191-21-067659 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 23:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-065618 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,630 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 23:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $32.67 | $44,921.25 |
DisclosureSEC source: 0001209191-21-065618 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 23:51 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-065618 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 20:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-062707 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,005 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 20:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $36.94 | $50,792.50 |
DisclosureSEC source: 0001209191-21-062707 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 20:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-062707 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-061274 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,380 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $38.87 | $53,446.25 |
DisclosureSEC source: 0001209191-21-061274 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-061274 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 22:26 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-059853 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,755 Underlying: Common Stock · 1,375 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 22:26 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 1,375 | $33.75 | $46,406.25 |
DisclosureSEC source: 0001209191-21-059853 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
| October 05, 2021 Filed Oct 6, 2021 22:26 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 1,375 | $1.53 | $2,103.75 |
DisclosureSEC source: 0001209191-21-059853 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-057641 · doc4.xml · derivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,130 Underlying: Common Stock · 8,000 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 8,000 | $1.53 | $12,240.00 |
DisclosureSEC source: 0001209191-21-057641 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 23:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-057317 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,130 Underlying: Common Stock · 4,125 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 23:34 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 4,125 | $50.00 | $206,250.00 |
DisclosureSEC source: 0001209191-21-057317 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.